Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home





Announcement

Submit new announcement
Ronny I. Drapkin, M.D.,Ph.D.

Assistant Professor of Pathology, Harvard Medical School
Principal Investigator


Academic Activities:
Research in the Drapkin laboratory focuses on understanding the pathogenesis and genetic alterations involved in women’s cancers, with a specific interest in ovarian cancer. A major goal is to translate what is learned at the bench into clinically useful diagnostic and therapeutic tools. To accomplish these goals, the laboratory focuses on three complementary approaches: (1) ovarian cancer genetics, (2) pathogenesis, and (3) biomarker development. All three approaches rely on integrated genomic studies, new cell culture model systems, and rigorous protein biochemistry and molecular biology.
Office
44 Binney Street
JFB-215D DFCI
Boston,MA 02115
Email1: ronny_drapkin@dfci.harvard.edu
Education and Training:

Medical School - : University of Medicine and Dentistry of New Jersey M.D.
Graduate School - : University of Medicine and Dentistry of New Jersey Ph.D.
Residency 7/1/98 - 6/30/2001 : Brigham and Women's Hospital
Fellowship 7/1/2001 - 8/30/2005 : Dana-Farber Cancer Institute

Clinical Specialties: Research Interests:
  • Ovarian cancer
  • Cell Proliferation
  • Cancer
  • Oncogenesis
  • Signalling pathway
  • Growth factor
  • Breast Cancer
  • Gene expression profiling
  • Marker identification
  • Pathogenesis
  • Transcriptional regulation
  • Cell Biology
Publication:
  1. Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor B Pathway and Is Associated with Poor Overall Survival. Adam Clauss, Vivian Ng, Joyce Liu, Huiying Piao, Moises Russo, Natalie Vena, Qing Sheng, Michelle S. Hirsch, Tomas Bonome, Ursula Matulonis, Azra H. Ligon, Michael J. Birrer, and Ronny Drapkin. Neoplasia (2010), 12, 161–172.
  2. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. K Levanon, V Ng, HY Piao, Yi Zhang, MC Chang, MH Roh, DW Kindelberger, MS Hirsch, CP Crum, JA Marto and R Drapkin. Oncogene (2010) 29, 1103–1113.
  3. Ovarian Cancer Pathogenesis: A Model in Evolution. Alison M. Karst and Ronny Drapkin. Journal of Oncology (2010), 2010, article ID 932371.
  4. An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Qing Sheng, Xinggang Liu, Eleanor Fleming, Karen Yuan, Huiying Piao, Jinyun Chen, Zeinab Moustafa, Roman K. Thomas, Heidi Greulich, Anna Schinzel, Sara Zaghlul, David Batt, Seth Ettenberg, Matthew Meyerson, Birgit Schoeberl, Andrew L. Kung, William C. Hahn, Ronny Drapkin, David M. Livingston, and Joyce F. Liu. Cancer Cell (2010) 17, 298–310.
  5. New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. Keren Levanon, Christopher Crum, and Ronny Drapkin. J Clinical Oncology (2008) 26, 5284-5293.
  6. A Novel Breast Cancer-Associated BRIP1 (FANCJ/BACH1) GermlineMutation Impairs Protein Stability and Function. Arcangela DeNicolo, Mariella Tancredi, Grazia Lombardi, Cristina Chantal Flemma, Serena Barbuti, Claudio DiCristofano, Bijan Sobhian, Generoso Bevilacqua, Ronny Drapkin, and Maria Adelaide Caligo. Clin Cancer Res (2008) 14, 4672-4680.
  7. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen S-M, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma V-M, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-319.
  8. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-2169
  9. Drapkin R, Crum CP, Hecht JL. Expression of Candidate Tumor Markers in Ovarian Carcinoma and Benign Ovary: Evidence for a link between epithelial phenotype and neoplasia. Human Pathol 2004; 35: 1014-1021.
  10. Cantor S*, Drapkin R*, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. PNAS 2004; 101: 2357-2362. (* denotes equal contribution).
<December 2017>
SuMoTuWeThFrSa
262728293012
3456789
10111213141516
17181920212223
24252627282930
31123456


<Friday, December 15, 2017>
8:00 AM
Dr. Eleanor Russell-Goldman, Dr. Kristine Wong
Cotran Conference Center
9:15 AM

Autopsy suite
12:00 PM

GYN 14-headed scope
1:00 PM
Dr. Christopher Fletcher
Cotran Conference Center
Copyright 2008 - 2017, BWH Pathology, All rights reserved.